Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness study of daptomycin versus vancomycin for gram-positive bacteremia and infective endocarditis
ChiCTR1800019619Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Nov 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of daptomycin and vancomycin in Gram-positive bacteremia (GPB) and endocarditis (IE) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Cost-effectiveness ratio. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
daptomycinvancomycin
03
Conditions
Gram-positive bacteremia (GPB)endocarditis (IE)
Beyond the preview
Go deeper on ChiCTR1800019619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019619.